


DPX-0907 CANCER VACCINE: STRENGTH & SPECIFICITY COMBINED




DPX-0907 TREATMENT GROUP



VS.

UNTREATED CONTROL GROUP



DPX-0907: THE STRENGTH OF DEPOVAX & THE SPECIFICITY OF 7 CANCER ANTIGENS COMBINED

DPX-0907

A therapeutic cancer vaccine that creates a “depot” at the injection site, specifically developed to treat breast, ovarian and prostate cancer.

DEPOVAX™

A multipurpose and powerful vaccine delivery technology
Pre-clinical studies show 100% tumor elimination with a single dose
Does not promote Tregs activation that negate the benefits of the vaccine
Easy to use, chemically stable and flexible
Increases specific CTL response



7 CANCER ANTIGENS

Cancer specific peptides found on surface of tumor cells stimulate T cell recognition and destruction of cells with the cancer “signature”
Induce specific recognition of tumor cells by the immune system
Target major pathways of cancer
Pre-clinically and clinically validated antigens

DPX-0907 CANCER VACCINE SIGNIFICANCE

A rapid, non-invasive approach that activates the immune system to prevent metastasis and eliminate microscopic tumors

Strong and specific CTL response that kills cancer cells


Unlike other vaccines, does not induce regulatory T-cell mediated immune suppression, ensuring prolonged activity

Excellent safety profile, with antigens designed to work in conjunction with chemotherapy

Novel formulation creates a “depot” at site of injection causing a strong, rapid and long-lasting cellular response

Phase 1 clinical trial in breast, ovarian and prostate cancer at five centres in the US

DPX-0907 CLINICAL DEVELOPMENT



Phase 1 will look at the safety of DPX-0907 and the DepoVax™ Platform.

Immunovaccine is looking for partners to develop DPX-0907 following Phase I or II clinical trials. Partnership opportunities are also available to use IMV's patented DepoVax™ vaccine delivery technology.

1. Daftarian et al., Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome encapsulated CTL-T helper fusion peptide in a water in oil emulsion, *Vaccine*, 24 (2006), 5235-5244
2. Daftarian et al., Rejection of large HPV-16 expression tumors in aged mice by a single immunization of VacciMax® encapsulated CTL/T helper peptides, *Translational Medicine*, June 24, 2008.
3. Mansour et al., Therapy of established B16-F10 melanoma tumors by a single vaccination of CTL/T helper peptides in VacciMax®, *Translational Medicine*, April 23, 2007.
4. Karkada et al., A Novel Breast/Ovarian Cancer Peptide Vaccine Platform That Promotes Specific Type-1 but not Treg/Tr1-type Responses, *Journal of Immunotherapy*, Vol. 33, No. 3, April 2010